Loading...
Loading...
The FDA has approved the
addition of a secondary supplier of Methoxsalen USP, an integral component of
a treatment for the relief of moderate to severe psoriasis prescribed under
the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.
"We are pleased to obtain FDA approval of an additional manufacturer of
Methoxsalen, the key active ingredient for this important drug," said David
Mullarkey, senior vice president and general manager of Valeant Dermatology, a
division of Valeant Pharmaceuticals North America LLC. "This approval enables
us to ensure a steady supply of Oxsoralen-Ultra and is a key step in restoring
the supply of our other Methoxsalen containing drug products."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in